Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, 01323-001, Brazil
NCT Number: NCT07020832
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
São Paulo, 01323-001, Brazil
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
If you haven't had these vaccines, you may still qualify to be part of the study, provided your doctor plans to administer preventive antibiotics until vaccination can be given per protocol, and with notification to the sponsor.
Exclusion criteria
Complement (C3) Inhibitor
Sterile solution of equal volume to active arm
Time frame: Duration of dialysis through day 90
To assess the efficacy of pegcetacoplan compared with that of placebo in participants at high risk of DGF following donor kidney allograft transplant surgery
Time frame: 52 weeks following surgery
To evaluate the efficacy of pegcetacoplan in reducing the severity of DGF and consequent improvements in short-, medium- and long-term kidney function and kidney allograph outcomes
Time frame: 7 days following surgery
To evaluate the efficacy of pegcetacoplan in reducing the severity of DGF and consequent improvements in short-, medium- and long-term kidney function and kidney allograph outcomes
Time frame: 90 days following surgery
To evaluate the efficacy of pegcetacoplan in reducing the severity of DGF and consequent improvements in short-, medium- and long-term kidney function and kidney allograph outcomes
Time frame: 14 days following surgery
To evaluate the efficacy of pegcetacoplan in reducing the severity of DGF and consequent improvements in short-, medium- and long-term kidney function and kidney allograph outcomes
Time frame: 52 weeks following surgery
To evaluate the efficacy of pegcetacoplan in reducing the severity of DGF and consequent improvements in short-, medium- and long-term kidney function and kidney allograph outcomes
Apellis Pharmaceuticals, Inc.
Industry
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01848249
Acute Kidney Injury, Chronic Disease
New Haven, Connecticut, United States
View Trial DetailsNCT02134314
Chronic Disease, Delayed Graft Function
Los Angeles, California, United States
View Trial DetailsNCT03829488
Chronic Disease, Delayed Graft Function
Randwick, New South Wales, Australia
View Trial DetailsNCT03071536
Delayed Graft Function, Kidney Function
Bangkok, Thailand
View Trial Details